Brief: Kamada Announces Strategic Transformational Transaction

Kamada

22/11/2021 12:38

Nov 22 (Reuters) - Kamada Ltd  KMDA.TA :
    * KAMADA ANNOUNCES STRATEGIC TRANSFORMATIONAL TRANSACTION
POSITIONING THE COMPANY AS A GLOBAL LEADER IN THE PLASMA-DERIVED
HYPERIMMUNE MARKET THROUGH THE ACQUISITION OF A PORTFOLIO OF
FOUR FDA-APPROVED COMMERCIAL PRODUCTS
    * KAMADA - UNDER TERMS OF AGREEMENT, KAMADA WILL PAY SAOL A
$95
MILLION UPFRONT PAYMENT, AND UP TO AN ADDITIONAL $50 MILLION IN
SALES MILESTONES DURING 2022-2034
    * KAMADA - ACQUIRED PORTFOLIO OF FOUR U.S. FDA-APPROVED
PLASMA-DERIVED HYPERIMMUNE COMMERCIAL PRODUCTS FROM SAOL
THERAPEUTICS

Source text for Eikon:  ID:nGNXcdYFsf 
Further company coverage:  KMDA.TA 

 ((Reuters.Briefs@thomsonreuters.com;))